The two types of imaging catheter, as guides for coronary stent targeting and deployment, led to similar clinical outcomes in the OCTIVUS trial. A meta-analysis backed it up.
In Denmark, 1-year mortality after percutaneous coronary intervention for STEMI was reduced by about 30% from 2003 to 2018; most of the reduction was seen within the first 30 days after the procedure.
Using prasugrel (Effient) alone in the first month after PCI did not reduce bleeding risk and there was a suggestion of possible increased ischemic risk vs dual antiplatelet therapy, in a new trial.
Prasugrel monotherapy after percutaneous coronary intervention (PCI) with drug-eluting stents is not superior to dual-antiplatelet therapy (DAPT) for major bleeding but is non-inferior for cardiovascular events in patients with acute coronary syndrome (ACS) or high bleeding risk (HBR), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.
The Drug Device Combination Products Market size is expected to grow from USD 125.70 billion in 2023 to USD 166.63 billion by 2028, at a CAGR of 5.80%.